Virologic Response and Safety After Oral Administration of Ibuzatrelvir, a Novel SARS-CoV-2 M^{pro} Inhibitor, in **Non-Hospitalized Adults With Symptomatic COVID-19**

Mahta Mortezavi,^{1*} Abigail Sloan,² Ravi Shankar P. Singh,² Luke F. Chen,² Negin Shojaee,² Jin Hyang Kim,³ Anindita Banerjee,² Arthur Bergman,¹ Charlotte Allerton,² Negar Niki Alami¹

¹Pfizer Inc, New York, NY, USA; ²Pfizer Inc, Cambridge, MA, USA; ³Pfizer Inc, Collegeville, PA, USA

*Presenting author

INTRODUCTION

Although vaccination has had a dramatic impact on outcomes for patients with SARS-COV-2 infection, new variants continue to evade immune

Patient Population

Out of 240 enrolled patients, 199 (82.9%) were qualified for the mFAS.

Figure 2. LS Mean Change From Baseline in Nasopharyngeal Viral Load Over Time (Modified Full Analysis Set)

- response, leading to symptomatic disease and a substantial burden on global healthcare systems.¹⁻³
- In January 2024 alone, the World Health Organization recorded 315,748 new cases of COVID-19 across reporting countries in Europe, illustrating the continued burden of the disease.⁴
- For the management of non-hospitalized adults with mild to moderate COVID-19 who are at high risk of disease progression, both the European Society of Clinical Microbiology and Infectious Diseases and the United States National Institutes of Health recommend nirmatrelvir/ritonavir (Paxlovid[®]) as the preferred therapy.^{5,6}
- Like nirmatrelvir, ibuzatrelvir is an orally bioavailable, potent SARS-CoV-2 main protease (M^{pro}) inhibitor that has demonstrated pan-human coronavirus antiviral activity in vitro and in preclinical animal studies.⁷⁻⁹
- Ibuzatrelvir can achieve high systemic concentrations without the need for pharmacokinetic enhancement (eg, ritonavir), and in vivo and in vitro studies suggest that the drug-drug interaction (DDI) potential is likely to be minimal.^{7,9}

OBJECTIVE


• The goal of this study (NCT05580003) was to evaluate the virologic response and safety of different doses of ibuzatrelvir among nonhospitalized, symptomatic 18- to <65-year-old patients with rapid antigen test (RAT)–confirmed SARS-CoV-2 infection.



- Demographics and clinical characteristics of the 199 participants in the mFAS were similar across treatment groups (Table 1).

Table 1 Demographic and Clinical Characteristics (Modified Full

		Ibuzatrelvir (n=135)			
Characteristic	Placebo (n=64)	100 mg (n=36)	300 mg (n=28)	600 mg (n=71)	
Median age (range), years	41.5 (19–64)	47.5 (22–61)	41.0 (24–61)	43.0 (19–64	
Sex, n (%)					
Female	36 (56.3)	20 (55.6)	21 (75.0)	43 (60.6)	
Race, n (%)					
White	55 (85.9)	35 (97.2)	25 (89.3)	56 (78.9)	
Black	5 (7.8)	0 (0.0)	1 (3.6)	9 (12.7)	
Asian	2 (3.1)	1 (2.8)	2 (7.1)	5 (7.0)	
Ethnicity, n (%)					
Hispanic or Latino	50 (78.1)	0 (86.1)	23 (82.1)	58 (81.7)	
Body mass index, kg/m	2				
Median (range)	27.3 (19.4–29.9)	27.9 (19.0–29.8)	27.8 (18.2–29.8)	27.8 (18.5–29.9)	
Duration since first sym	ptom, days				
Median (range)	2.0 (0-4)	2. (0–5)	2.0 (0-5)	2.0 (0-4)	
SARS-CoV-2 vaccination	on status, n (%)*				
Complete	38 (59.4)	24 (66.7)	23 (82.1)	54 (76.1)	
SARS-CoV-2 serology	status, n (%) anti-	-SARS-CoV-2 a	nti-N antibody		
Negative	12 (18.8)	10 (27.8)	2 (7.1)	17 (23.9)	
Positive	52 (81.3)	26 (72.2)	26 (92.9)	54 (76.1)	
SARS-CoV-2 serology	status, n (%) anti-	-SARS-CoV-2 a	nti-S antibody		
Positive	64 (100)	36 (100)	28 (100)	70 (98.6)	
SARS-CoV-2 viral load	, log ₁₀ copies/mL				
Median (range)	6.2 (4.1–9.6)	6.3 (4.3–9.1)	5.9 (4.1–8.4)	6.3 (4.1–9.1	



Safety Assessments

RESULTS

Study Design and Patients

- This phase 2b, randomized, double-blind, parallel-group, dose-ranging study enrolled participants aged ≥18 to <65 years across the United States who had ≤5 days of symptomatic SARS-CoV-2 infection confirmed by RAT of a nasopharyngeal (NP) specimen collected within 48 hours before randomization.
 - Eligible participants had onset of COVID-19 symptoms within 5 days before randomization and ≥ 1 specified COVID-19 symptom on the day of randomization.
 - Individuals were excluded from the study if they had any of the following underlying conditions: body mass index \geq 30 kg/m², current smoker status, chronic lung disease, asthma requiring daily therapy, oxygen saturation <92% on room air, known history of cardiovascular disease, kidney disease requiring dialysis or known renal impairment with an estimated glomerular filtration rate $<30 \text{ mL/min}/1.73 \text{m}^2$, neurodevelopmental disorder, active cancer, history of liver disease, or immunocompromised status.
- Participants were randomized in a 1:1:2:2 ratio (Figure 1) to receive a 100-mg, 300-mg, or 600-mg dose of ibuzatrelvir or placebo orally every 12 hours (±4 hours) for 5 days. NP swabs were collected at baseline and Days 3, 5, 10, 14, and 21 for all participants, and SARS-CoV-2 RNA levels (viral load [VL]) were measured by RT-PCR as previously reported.¹⁰

Figure 1. Study Design, Treatment Assignments, and Follow-Up

Screening		Treatment Days	Follow-Up			
Day –1 to 1	1:1:2:2	1 3 5	10 14	21 33		
Nasopharyngeal specimens collected	specimens	Placebo 100 mg twice a day	Nasopharyngeal specimens collected	Vital signs assessed Adverse events		
Adverse events recorded	Rar	300 mg twice a day	Adverse events recorded	recorded (In-person visit		
(In-person visit)	600 mg twice a day	(In-person visit)	or Telehealth)			

Change From Baseline in Viral Load

- On Day 5, participants receiving ibuzatrelvir at any dose experienced significantly greater reductions in VL from baseline compared with placebo (Table 2, Figure 2).
- Differences in CFB VL between treatment and placebo arms were also significant across all dosing groups on Day 3 (Table 2, Figure 2).

Table 2. LS Mean Change From Baseline and Difference From Placebo in Nasopharyngeal Viral Load (Modified Full Analysis Set)

Treatment Group	n	LS Mean (80% CI) Change From Baseline	LS Mean Difference From Placebo (80% Cl) in Change From Baseline	<i>P</i> value
Placebo	63	-1.3 (-1.6, -1.0)		
Ibuzatrelvir 100 mg	35	-2.0 (-2.4, -1.7)	-0.7 (-1.2, -0.3)	0.0114
Ibuzatrelvir 300 mg	27	-2.5 (-3.0, -2.1)	-1.2 (-1.7, -0.8)	0.0003
Ibuzatrelvir 600 mg	70	-2.5 (-2.8, -2.2)	-1.2 (-1.5, -0.8)	<.0001
Placebo	60	-3.2 (-3.5, -2.9)		
Ibuzatrelvir 100 mg	34	-3.9 (-4.2, -3.5)	-0.7 (-1.1, -0.3)	0.0181
Ibuzatrelvir 300 mg	24	-4.0 (-4.5, -3.6)	-0.8 (-1.3, -0.3)	0.0127
Ibuzatrelvir 600 mg	66	-4.4 (-4.7, -4.1)	-1.2 (-1.5, -0.8)	<0.0001
	Placebo Ibuzatrelvir 100 mg Ibuzatrelvir 300 mg Ibuzatrelvir 600 mg Ibuzatrelvir 100 mg Ibuzatrelvir 300 mg	Placebo63Ibuzatrelvir 100 mg35Ibuzatrelvir 300 mg27Ibuzatrelvir 600 mg70Placebo60Ibuzatrelvir 100 mg34Ibuzatrelvir 300 mg24	Treatment Groupn(80% Cl) Change From BaselinePlacebo63-1.3 (-1.6, -1.0)Ibuzatrelvir 100 mg35-2.0 (-2.4, -1.7)Ibuzatrelvir 300 mg27-2.5 (-3.0, -2.1)Ibuzatrelvir 600 mg70-2.5 (-2.8, -2.2)Placebo60-3.2 (-3.5, -2.9)Ibuzatrelvir 100 mg34-3.9 (-4.2, -3.5)Ibuzatrelvir 300 mg24-4.0 (-4.5, -3.6)	Image:

Percentages of Participants With Viral Load <LLOQ

- All doses were well tolerated and had a safety profile similar to placebo through Day 33 (Table 3).
- No participants reported dysgeusia.
- There were no treatment-related grade 3/4 AEs, SAEs, or deaths from any cause in this study.

Table 3. Summary of AEs, SAEs, and Subsequent Discontinuations Through Day 33 (Safety Analysis Set)

		lbuz	Ibuzatrelvir (n=158)		
	Placebo (n=79)	100 mg (n=40)	300mg (n=39)	600 mg (n=79)	
AEs during treatment or follow up			·		
Number of AEs	12	3	9	25	
Participants with AEs, n(%)					
Any AE	9 (11.4)	2 (5.0)	5 (12.8)	11 (13.9)	
SAE	0	0	1 (2.6)*	0	
Grade 3 or 4 AE	0	0	1 (2.6)*	0	
Death from any cause	0	0	0	0	
AE leading to discontinuation of participation in trial	0	0	1 (2.6)†	0	
AE leading to discontinuation of ibuzatrelvir or placebo; trial participation continued	0	0	0	1 (1.3) [‡]	
AEs considered related to ibuzatrel	vir or place	bo			
Number of AEs	5	1	2	3	
Participants with AEs, n(%)					
Any AE	4 (5.1)	1 (2.5)	2 (5.1)	2 (2.5)	
SAE	0	0	0	0	
Grade 3 or 4 AE	0	0	0	0	
AE leading to discontinuation of participation in trial	0	0	1 (2.6)†	0	
AE leading to discontinuation					

Assessments and Statistical Analyses

- The primary endpoint was change from baseline (CFB) in VL at Day 5 across all treatment arms and was evaluated in the modified full analysis set (mFAS), which included participants who received ≥1 dose of the study intervention and who had a baseline VL \geq 4 log₁₀ copies/mL.
- Additional secondary virologic endpoints evaluated in the mFAS included CFB in VL at Days 3, 10, and 14 and proportion of patients with VL levels <2 log₁₀ copies/mL (lower limit of quantification [LLOQ]) at Days 3, 5, 10, and 14.
- Differences in VL were analyzed using a mixed model for repeated measures (MMRM) with a 1-sided alpha of 0.1.
- Safety and tolerability through Day 33 were evaluated in the safety analysis set, which included all participants who received ≥1 dose of the study drug; assessments included incidence of treatment-emergent adverse events (AEs); serious AEs (SAEs); and AEs leading to study discontinuation.

A higher percentage of participants receiving ibuzatrelvir had VL <LLOQ compared with placebo on Days 3 and 5; percentages were similarly high across all treatment arms on Days 10 and 14, and therefore no meaningful differences between dosing groups and placebo were observed at these time points (data not shown).



AE, adverse event; SAE, serious adverse event

*Exacerbation of a pre-existing condition (first degree atrioventricular conduction block caused by uncontrolled hypertension) [†]Participant withdrew from the study due to vomiting (mild; treatment-related)

[‡]Participant discontinued treatment due to elevation from baseline levels of liver enzymes (mild/moderate severity)

CONCLUSIONS

- Ibuzatrelvir is an oral SARS-CoV-2 M^{pro} inhibitor without the need for pharmacokinetic enhancement and with low potential for DDIs.^{7,9}
- In this study, ibuzatrelvir showed robust antiviral activity across all doses, with statistically significant, dose-dependent decreases in VL relative to placebo at Days 3 and 5.
- All doses were well tolerated with a safety profile similar to placebo and no reports of dysgeusia (a reported AE during treatment with nirmatrelvir/ ritonavir).⁸

References

- 1. Satapathy P, et al. New Microbes New Infect. 2024;57:101225.
- 2. Jain V. et al. Int J Public Health. 2022:67:1604793.
- 3. Brnic S, et al. Vaccine X. 2023;15:100391
- 4. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Available at: https://covid19.who.int/. Accessed March 12, 2024
- 5. National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Available at:
- https://www.covid19treatmentguidelines.nih.gov/. Accessed February 27, 2024.
- Bartoletti M, et al. Clin Microbiol Infect. 2022;28(12):1578-1590.
- 7. Tuttle J. Discovery of PF-07817883: A next generation oral protease inhibitor for the treatment of COVID-19. Presented at: American Chemical Society Fall 2023, August 13-17, 2023; San Francisco, CA.
- 8. Paxlovid (nirmatrelvir tablets; ritonavir tablets). Full Prescribing Information, Pfizer Inc, New York, NY, 2023.
- 9. Allerton C, et al. Journal of Medicinal Chemistry. 2024; In press. 10. Hammond J, et al. N Engl J Med. 2022;386(15):1397-1408.

Acknowledgments

This study was sponsored by Pfizer Inc. Medical writing support was provided by Amish Vora, PharmD, and Anna Stern, PhD, of ICON (Blue Bell, PA) and was funded by Pfizer.

Disclosures

All authors are employees of Pfizer and may hold stock or stock options.

For more information please contact Dr. Mahta Mortezavi Pfizer Inc 66 Hudson Blvd

New York, NY 1000² Pfizer Inc, New York, NY, USA Email: Mahta.mortezavi@pfizer.com Telephone: 716-348-6078



Presented at the European Congress of Clinical Microbiology and Infectious Disease (ECCMID) 2024; April 27–30, 2024; Barcelona, Spain